Please try another search
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Yoram Drucker | 58 | 2022 | Co-Founder, VP of Strategic Development & Chairman |
Michael Belkin | 82 | - | Member of Scientific Advisory Board |
Gabriel Zeilig | - | - | Member of Scientific Advisory Board |
Nahshon Knoller | - | - | Member of Scientific Advisory Board |
Shulamit Levenberg | 60 | - | Member of Scientific Advisory Board |
Daniel Offen | - | - | Member of Scientific Advisory Board |
Gadi Riesenfeld | - | 2023 | Independent Director |
Teodoro Forcht Dagi | 74 | 2023 | Member of Scientific Advisory Board |
James A. Richardson | 79 | 2011 | Independent Director |
Oded Orgil | 56 | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review